<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-161634</identifier>
<setSpec>0001-7310</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Inflammatory bowel disease: joint management in gastroenterology and dermatology</dc:title>
<dc:description xml:lang="en">Inflammatory bowel disease (IBD) is a complex entity that includes Crohn disease and ulcerative colitis. It is characterized by a chronic proinflammatory state of varying intensity that often leads to considerable morbidity. In the last decade, several therapeutic targets have been identified that are susceptible to the use of biological agents, including anti-tumor necrosis factor alpha antibodies, which are associated with paradoxical psoriasiform reactions in 5% of patients. Decision-making in the management of these cases requires close collaboration between the dermatologist and gastroenterologist. Inflammatory bowel disease is also associated with various other dermatologic and rheumatologic manifestations, and presents a genetic and pathogenic association with psoriasis that justifies both the interdisciplinary approach to these patients and the present review (AU)</dc:description>
<dc:creator>Puig, L</dc:creator>
<dc:creator>Laiz, A</dc:creator>
<dc:creator>Garcia-Planella, E</dc:creator>
<dc:creator>Sánchez-Martínez, MA</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La enfermedad inflamatoria intestinal es una entidad compleja que incluye la enfermedad de Crohn y la colitis ulcerosa, y se caracteriza por un estado proinflamatorio crónico con un curso oscilante y que en muchas ocasiones conlleva una gran morbilidad a estos pacientes. En la última década se han identificado distintas dianas terapéuticas que permiten el uso de fármacos biológicos, en particular los anticuerpos dirigidos contra el factor de necrosis tumoral alfa, que se asocian en un 5% de los casos con reacciones paradójicas psoriasiformes, que requieren una estrecha colaboración entre el dermatólogo y el gastroenterólogo en la toma de decisiones. La enfermedad inflamatoria intestinal se asocia, asimismo, a otras diversas manifestaciones dermatológicas y reumatológicas, y presenta una asociación genética y patogénica con la psoriasis, que justifica tanto el abordaje interdisciplinario de estos pacientes como la presente revisión (AU)</dc:description>
<dc:source>Actas Dermosifiliogr;108(3): 184-191, abr. 2017. tab, ilus</dc:source>
<dc:identifier>ibc-161634</dc:identifier>
<dc:title xml:lang="es">Enfermedad inflamatoria intestinal: abordaje conjunto digestivo-dermatológico</dc:title>
<dc:subject>^d23695^s22053</dc:subject>
<dc:subject>^d23973^s22012</dc:subject>
<dc:subject>^d23971^s22012</dc:subject>
<dc:subject>^d36005^s22012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d31092^s22002</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d23695^s22016</dc:subject>
<dc:subject>^d23695^s22027</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d24572</dc:subject>
<dc:subject>^d12002^s22012</dc:subject>
<dc:type>article</dc:type>
<dc:date>201704</dc:date>
</metadata>
</record>
</ibecs-document>
